Share This Page
Drug Price Trends for HEADACHE RELIEF CAPLET
✉ Email this page to a colleague
Average Pharmacy Cost for HEADACHE RELIEF CAPLET
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| HEADACHE RELIEF CAPLET | 70000-0146-01 | 0.06334 | EACH | 2025-03-19 |
| HEADACHE RELIEF CAPLET | 70000-0146-01 | 0.06420 | EACH | 2025-02-19 |
| HEADACHE RELIEF CAPLET | 70000-0146-01 | 0.06280 | EACH | 2025-01-22 |
| HEADACHE RELIEF CAPLET | 70000-0146-01 | 0.06407 | EACH | 2024-12-18 |
| HEADACHE RELIEF CAPLET | 70000-0146-01 | 0.06295 | EACH | 2024-11-20 |
| HEADACHE RELIEF CAPLET | 70000-0146-01 | 0.06531 | EACH | 2024-10-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Headache Relief Caplets
Market Overview
The market for headache relief caplets, such as those containing acetaminophen and caffeine, is part of the broader migraine and headache therapeutics market. Here’s a detailed analysis of the market trends, growth projections, and key factors influencing the prices of these products.
Global Migraine and Headache Therapeutics Market
The global migraine therapeutics market is expected to experience significant growth over the coming years. By 2030, the market is projected to reach USD 9.16 billion, growing at a CAGR of 6.84% from 2025 to 2030[3].
Segmentation and Growth Drivers
CGRP Antagonists and Monoclonal Antibodies
The segment dominated by calcitonin gene-related peptide (CGRP) antagonists, including monoclonal antibodies (mAbs) and oral gepants, is a major growth driver. These drugs have shown superior efficacy and tolerability compared to traditional treatments like triptans, antidepressants, anticonvulsants, and beta blockers. CGRP mAbs held a significant market share of 57.27% in 2023, driven by their effectiveness in preventing migraine attacks and improving health-related quality of life[1][4].
Over-the-Counter (OTC) Headache Relief
OTC headache relief products, such as Excedrin Tension Headache Relief, which contains acetaminophen and caffeine, continue to be popular for minor aches and pains. These products are widely available and trusted for their formulation in relieving headache and muscular aches[2].
Price Projections and Factors Influencing Prices
CGRP Antagonists and Monoclonal Antibodies
The prices of CGRP antagonists and mAbs are significantly higher than those of traditional headache medications. For instance, the annual costs of therapy for these drugs are substantially higher compared to generic drugs. However, their benefits in terms of more migraine-free days and improved quality of life justify the higher costs. Each migraine-free day achieved with CGRP mAbs can result in savings ranging from USD 130 to USD 340[1].
OTC Headache Relief Products
OTC products like Excedrin are generally more affordable and accessible. Their prices are influenced by production costs, market competition, and consumer demand. Given their widespread use and established market presence, these products tend to have stable pricing.
Market Growth and Forecast
Global Market Size
The global migraine drugs market was estimated at USD 5.64 billion in 2023 and is projected to grow at a CAGR of 11.9% from 2024 to 2030. This growth is driven by the increasing prevalence of migraines and the approval of new drugs[1].
Regional Market
Across the seven major markets (7MM), the migraine market is expected to grow from USD 9.2 billion in 2023 to USD 16.4 billion by 2033, at a CAGR of 6.0%. This growth will be primarily driven by the increased prescription of CGRP antagonists and oral gepants[4].
Late-Stage Pipeline and Future Trends
Several late-stage pipeline products are expected to enter the market, targeting both acute and preventive treatments. While there is a focus on reformulations and combination therapies, novel mechanisms of action, such as Lundbeck’s anti-pituitary adenylate cyclase-activating polypeptide (PACAP) mAb, are seen as promising for meeting the unmet need for novel preventive therapies[4].
Reimbursement and Regulatory Factors
The growth of the market, especially for high-cost CGRP antagonists, will be influenced by reimbursement restrictions and patent expiries. For example, Pfizer’s Nurtec, approved for both acute and preventive therapy, is expected to peak in sales before its patent expires in the early 2030s, leading to significant generic erosion[4].
Consumer Demand and Awareness
Increasing awareness about migraine disorders and their diagnosis and treatment measures among the global population is anticipated to drive market growth. The high consumer base and unmet need for effective medicines worldwide push pharmaceutical giants to develop and commercialize new drugs[1].
Key Takeaways
- The global migraine therapeutics market is expected to grow significantly, driven by the increasing prevalence of migraines and the approval of new drugs.
- CGRP antagonists and mAbs dominate the market due to their efficacy and tolerability.
- OTC headache relief products remain popular for minor aches and pains.
- Price projections are influenced by the high costs of CGRP antagonists and the stability of OTC product prices.
- Late-stage pipeline products and novel mechanisms of action are expected to further drive market growth.
Frequently Asked Questions (FAQs)
What is the projected growth rate of the global migraine drugs market?
The global migraine drugs market is projected to grow at a CAGR of 11.9% from 2024 to 2030[1].
Which segment dominates the migraine drugs market?
The CGRP monoclonal antibodies segment dominated the market with a market share of 57.27% in 2023[1].
What are the key drivers of the migraine therapeutics market?
Key drivers include the increasing prevalence of migraines, approval of new drugs, and the efficacy and tolerability of CGRP antagonists and mAbs[1][4].
How do OTC headache relief products fit into the market?
OTC products like Excedrin are popular for minor aches and pains, offering a trusted and accessible solution for consumers[2].
What impact do reimbursement restrictions have on the market?
Reimbursement restrictions and patent expiries are expected to limit the growth of high-cost CGRP antagonists and lead to significant generic erosion[4].
Cited Sources:
- Grand View Research - Migraine Drugs Market Size, Share & Trends Report, 2030
- Excedrin - Excedrin Tension Headache Relief
- Mordor Intelligence - Migraine Therapeutics Market Size & Share Analysis
- Clinical Trials Arena - Migraine market expected to reach $16.4bn across 7MM by 2033
More… ↓
